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Association of decreased quality of life and erectile dysfunction patients. Erectile dysfunction (ED) is common, occurring
in hemodialysis patients. in 82% of hemodialysis patients [2]. Our previous work
Background. Quality of life in hemodialysis patients has been demonstrated a prevalence of severe ED of 45% (95%associated with treatment outcomes. We explored the impact
CI, 36% to 55%) among HD patients using standardizedof erectile dysfunction on quality of life in a cohort of hemodial-
ysis subjects. self-reporting instruments. Subjects younger than 50
Methods. A random sample of 302 Philadelphia area hemo- years had a prevalence of ED of 63% (95% CI, 53% to
dialysis (HD) subjects was enrolled using a cross-sectional de- 71%), while in subjects 50 years or older it was 90% (95%sign. Subjects completed a self-administered questionnaire in-
CI, 84% to 94%). A multivariable analysis demonstratedcluding items on sexual function, past medical history, and
increasing age (50 to 59 years, OR  2.04, 95% CI, 1.3quality of life. Linear regression (accounting for sampling de-
sign by weighted estimation methods) was used to examine the to 3.1; 60 to 69 years, OR  5.5, 95% CI, 1.9 to 15.6)
associations between various measures of quality of life (the and diabetes (OR  2.0, 95% CI, 1.2 to 3.3) to be inde-dependent variables) and erectile dysfunction (ED) and other
pendently associated with the presence of any level ofvariables (the predictor variables).
Results. We found the emotional domains of the SF-36, a multi- ED. The use of angiotensin-converting–enzyme inhibi-
purpose, short-form health survey with 36 questions, to be more tors was inversely associated with ED (OR  0.41, 95%
profoundly associated with ED than the physical domains. Us- CI, 0.17 to 0.98).ing the physical and mental components of the SF-12, a new
Although a wealth of evidence exists that addresses12-item short form health survey as predictors of ED, only the
mental composite score (MCS) was statistically significant after the multifactorial nature of ED in end-stage renal disease
adjusting for age and diabetes (P  0.008). Subjects with ED (ESRD) patients [2–9], the impact of ED on quality of
had significantly lower quality of life mean scores. In particular, life is not known. No prior study has specifically focusedED was associated with poorer social interaction (mean score
on the relationship between ED and quality of life amongdifference, 10.3, adjusted P  0.001), decreased emotional
well-being (12.9, adjusted P  0.005), more role limitations HD patients, despite the fact that ED is associated with
due to emotional problems (22.9, adjusted P  0.01), and poorer quality of life among men without kidney disease
poorer social function (17.8, P  0.001). [10]. This study sought to identify the associations be-Conclusion. Recent advances in therapies for ED warrant
tween ED and various quality-of-life domains.that the diagnosis and treatment of erectile dysfunction be
included in the global health assessment by the nephrologists
and primary care providers of patients with renal insufficiency,
as it may improve the quality of life of patients. METHODS
Study design and research population
We studied men aged 18 years or older in metropolitanThe population of hemodialysis (HD) patients is grow-
Philadelphia who were treated with chronic HD for ating, in part, because of longer survival [1], something that
least six months. We used a two-stage cluster samplinghas highlighted the importance of quality of life for these
design to create a study population from which we could
make population-based inferences [11]. In the first stage,Key words: quality of life, erectile dysfunction, epidemiology, hemodi-
alysis. we randomly selected 16 HD facilities from the 51 facili-
ties in the area, with the probability of each facility’sReceived for publication September 11, 2002
inclusion approximately proportional to its size, as mea-and in revised form December 10, 2002
Accepted for publication February 14, 2003 sured by its number of dialysis stations. In the second
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20 subjects who met the eligibility criteria. Subjects were physical impairments [15]. These two components are
summarized in the Index of Disease Severity (IDS) andexcluded if they were cognitively impaired or spoke no
English. We replaced subjects who refused or were ex- the Index of Physical Impairment (IPI). The IDS reflects
the severity of each of a selected list of 19 disease catego-cluded with alternate subjects until we enrolled 20 indi-
viduals from each facility. Using this sampling scheme, ries. The disease categories are rated using an explicit
list of symptoms, signs, and diagnostic tests indicatinglarger facilities had a higher probability of being selected,
but eligible individual patients within a facility had an the presence and increasing severity of each identified
condition. Level 1 characterizes a condition with littleapproximately equal probability of selection into the
study. Characterization of sexual function was the focus or no morbidity. Level 2 is asymptomatic controlled dis-
ease. Level 3 is an uncontrolled disease with moderateof an earlier publication in which additional details on
methods can be found [2]. or severe manifestations. Level 4 refers to an uncon-
trolled, life-threatening disease. The IPI is intended toThe University of Pennsylvania’s Institutional Review
Board and the review boards of the clinical centers caring act as a snapshot of the impact of all the conditions on
the patients’ functional abilities, where level 0 is normalfor study subjects approved this study.
function, level 1 is mild-to-moderate impairment, and
Data collection level 2 is serious-to-severe impairment. The IDS and IPI
are combined to yield a single ICED score. Higher scoresWe asked the selected subjects to complete a self-admin-
istered questionnaire that included items referring to sex- reflect greater severity of disease or impairment.
ual function, past medical history, and quality of life.
Quality of life
Sexual function The Kidney Disease Quality of Life-Short Form
(KDQOL-SF) [16] questionnaire was administered atEach subject completed a self-administered five-item,
previously validated questionnaire, the International In- the same time as the IIEF-5. This questionnaire, which
includes the SF-36 [17], is an abridged version of thedex of Erectile Function (IIEF-5) [12]. The IIEF-5 is an
abridged version of the 15-item International Index of KDQOL, [18] a validated disease-specific tool that as-
sesses issues related to quality of life for patients withErectile Function. [13]. The five items included in the
IIEF-5 address the National Institutes of Health defini- ESRD. Scores on the KDQOL-SF can range from 0 to
100; higher scores represent higher quality of life. Thetion of ED, discriminate well between men with and
without ED, and capture the severity of ED [12]. The elements selected for the KDQOL-SF have been shown
to demonstrate good reliability and validity in quantify-subjects’ ED was measured and categorized according
to severity using a five-level ordinal scale based on their ing quality of life among HD patients [16]. When subjects
could not complete the KDQOL independently, studyIIEF-5 score. A cutoff score of 21 (range of scores, 5 to
25) was used to define ED. Subjects with scores of 21 personnel administered the SF-12. The SF-12 is a 12-
item subset of the original 36 items of the SF-36 that canor less were considered to have ED. ED was classified
likewise into five validated severity levels, ranging from reproduce the physical and mental component summary
scale score of the SF-36 without substantial loss of infor-none (22 to 25) to severe (5 to 7). Subjects also catego-
rized their ED on a supplemental single-item scale as mation [19]. We calculated the summary scores using
the SF-36 summary measures manual. There were threenot impotent, minimally impotent, moderately impotent,
or completely impotent as defined by the responses “al- major steps, including standardization of scales (z-
scores), aggregation of scale scores, and transformationways,” “usually,” “sometimes,” or “never” able to get
and keep an erection sufficient for sexual intercourse, of summary scores.
respectively [14].
Depression
Comorbidity Depression was evaluated using two questions from
the KDQOL. Patients were asked to indicate how muchWe obtained medical and demographic data for each
subject from abstraction of dialysis records. Medical data time during the previous four weeks they had felt (a)
“so down in the dumps that nothing could cheer youcollected included measures of: health status; time on
dialysis; comorbid conditions; laboratory studies such as up,” and (b) “downhearted and blue.” A response of “a
good bit,” “most,” or “all” of the time was consideredhemoglobin, creatinine, albumin, and parathyroid hor-
mone; adequacy of dialysis; compliance with dialysis; an indication of depression.
prior transplantation; and current medications.
Statistical methodsThe Index of Co-Existing Disease (ICED) was used
to categorize patients’ comorbidities. ICED classifies sub- Our analyses sought to identify the associations be-
tween the presence or absence of ED and various qual-jects with ESRD on a four-point scale based on the
presence and severity of 19 medical conditions and 11 ity-of-life domains. Because of the two-stage sampling
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Table 1. Demographic and clinical characteristics of study cohort
% Among patients % Among patients
Variable with ED (N ) without ED (N ) P value
Age group
50 20.6 (39) 59.7 (26) 0.01
50–59 20.2 (50) 29.0 (15)
60–69 24.3 (58) 11.3 (6)
70 34.8 (83) 0 (0)
Racea
White 39.8 (97) 19.2 (10) 0.07
Black 56.9 (130) 77.3 (35)
Other 3.3 (4) 3.4 (2)
Duration on dialysis years
1 15.0 (33) 8.5 (4) 0.69
1–2 25.5 (61) 20.7 (11)
2–4 33.8 (81) 31.8 (13)
4 25.7 (59) 39.0 (19)
Hypertension
Yes 95.9 (223) 98.7 (46) 0.29
No 4.1 (11) 1.3 (1)
Diabetes
Yes 42.1 (94) 22.9 (12) 0.01
No 57.9 (140) 77.1 (35)
ACE inhibitors
Yes 26.1 (61) 45.8 (18) 0.04
No 73.9 (173) 54.2 (29)
Individual disease severity
1 2.8 (6) 1.3 (1) 0.68
2 61.9 (143) 67.1 (33)
3 35.3 (85) 31.7 (13)
Index of physical impairment
0 36.9 (83) 52.7 (26) 0.34
1 49.2 (118) 32.9 (13)
2 13.8 (31) 14.4 (7)
Index of coexistent disease
1 29.6 (65) 38.1 (19) 0.44
2 29.3 (71) 22.4 (11)
3 41.1 (97) 39.5 (17)
Cause of ESRD
Diabetes mellitus 38.3 (82) 19.5 (10) 0.01
Hypertension 43.3 (105) 54.1 (23)
Other 18.5 (41) 26.4 (14)
Smoking status
Never smoked 30.0 (59) 28.7 (12) 0.25
Smoked 40 packs 37.6 (75) 51.8 (21)
Smoked 40 packs 32.5 (72) 19.5 (8)
Alcohol useb
Does not drink 75.3 (169) 68.4 (34) 0.73
6 drinks/week 17.8 (44) 25.2 (8)
6 drinks/week 7.0 (14) 6.4 (4)
Mean (SE) patients with ED Mean (SE) patients without ED
Karnofsky index 80.98 (2.1) 86.46 (2.6) 0.07
a Includes American Indian, Asian, and Other/multiracial. There was no difference in estimates between models examining white vs. non-white; b Quantification
of ETOH consumption was done using the Khavari Alcohol Test [37]
Note: Due to missing values, total may not always equal 302.
design, all analyses accounted for the unequal probabili- We described continuous variables by their mean and
standard deviations (or standard errors), and categoricalties of selection of individual subjects in facilities of vary-
ing size and the clustered sampling, which affects the variables by the proportion in each category. Linear re-
gression (accounting for sampling design by weighted esti-variability of estimates. To account for unequal selection
probabilities, we used weighted estimation methods, mation methods) [11] was used to examine the associations
between various measures of quality of life (the dependentwith each subject’s sampling weight inversely propor-
tional to his probability of selection into the study. The variables) and ED and other variables (the predictor
variables). We explored different quality-of-life mea-probability of selection into the study was the probability
of selecting a given dialysis unit multiplied by the proba- sures in HD patients that we hypothesized a priori may
be associated with ED. For example, the emotional do-bility of selection of a given subject from that unit.
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Table 2. Results of Kidney Disease Quality of Life (KDQOL) questionnaire in ESRD study subjects (N  166)
All patients Patients with ED Patients without ED
Measure Mean (SD) Mean (SD) Mean (SD)
ESRD-targeted scales
Symptom/problem 73.8 (16.0) 73.0 (15.8) 76.9 (16.9)
Effects of kidney disease 63.1 (22.2) 61.3 (22.8) 68.9 (20.7)
Burden of kidney disease 47.3 (27.3) 46.1 (27.8) 53.6 (25.3)
Work status 28.7 (38.0) 26.2 (36.4) 37.6 (43.7)
Cognitive function 84.0 (16.9) 82.4 (17.7) 90.6 (11.3)
Quality of social interaction 78.7 (16.8) 77.7 (17.8) 83.1 (12.1)
Sexual function 79.5 (26.5) 69.9 (28.1) 97.7 (6.8)
Sleep 62.3 (21.2) 61.2 (22.1) 66.7 (17.6)
Social support 73.8 (27.9) 72.6 (29.5) 76.2 (20.6)
Dialysis staff encouragement 77.9 (21.3) 77.3 (21.2) 77.0 (22.9)
Patient satisfaction 67.1 (24.3) 65.1 (24.3) 72.7 (23.5)
36-item health survey scales
Physical functioning 54.2 (27.8) 50.6 (27.5) 73.6 (19.5)
Role-physical 33.6 (39.3) 29.8 (38.0) 52.7 (40.3)
Pain 71.4 (28.5) 69.7 (28.6) 80.6 (25.7)
General health perceptions 48.1 (21.1) 46.3 (20.9) 57.3 (20.8)
Emotional well-being 74.1 (17.6) 72.6 (18.2) 82.3 (11.8)
Role-emotional 59.8 (43.3) 55.7 (43.7) 77.2 (37.2)
Social function 65.4 (31.0) 62.7 (30.4) 80.5 (27.9)
Vitality 51.5 (19.0) 49.1 (19.2) 61.2 (16.6)
Overall health rating 61.7 (21.3) 59.9 (21.3) 65.5 (20.0)
mains of the SF-36 would be more profoundly associated versus 25.4% among participants. Therefore, the final
study sample was made up of 302 subjects.with ED than the physical domains.
Table 1 summarizes the subject characteristics withSubjects with missing data were not included when
and without ED. One hundred seventy-two (59%) sub-those variables were analyzed. For the SF-36, if a patient
jects were African American. Nine patients (2.6%) wereanswered at least half of the questions for a particular
Hispanic. The mean (SD) age was 59 (15) years. Four-domain, the mean of the nonmissing questions was used.
teen percent of subjects had been on HD for 6 monthsFor example, the “physical functioning” scale had 10
to 1 year, 26% for 1 to 2 years, 33% for 2 to 4 years,questions. If a patient answered five or more of the 10
and 28% for more than 4 years. The majority of patientsquestions, a “physical” score was calculated. However,
(97%) had hypertension and 39% had diabetes mellitus.for the mental and physical component summary scores,
The cause of ESRD was diabetes type 1 (17%), diabetesa patient needed to have nonmissing scores for each of
type 2 (18%), hypertension (46%), glomerulonephritisthe 8 domains (physical, physical role, emotional role,
(2%), cystic disease (4%), and other (12%). The medicalsocial, mental, body pain, vitality, general). For the SF-
history and physiologic parameters of this study popula-12, a patient needed to complete all questions to have
tion have been described previously [2].a nonmissing mental component score and physical com-
There were 167 subjects who completed the KDQOL-ponent score. Analyses were performed using the survey
SF; 135 completed the SF-12. However, there were stillestimation facilities of STATA, version 7 (Stata Corpo-
some missing data for various questions. All availableration, College Station, TX, USA) and SAS version 6.12
data were used for each calculation. For instance, data(SAS Institute, Cary, NC, USA).
were available from 162 men for the “symptom/problem
list” scale of the KDQOL, but from only 159 men for
RESULTS “dialysis staff encouragement.” Complete information
We identified 482 of 705 potentially eligible men re- needed to score the SF-12 was available for 266 patients.
ceiving hemodialysis in the 16 facilities, as has been pre- Patients who filled out the abbreviated questionnaire
viously reported [2]. Twenty-seven men were excluded were older (66 vs. 55 years, P  0.0001) and had a
because of cognitive impairment. Thirty-seven men were higher index of coexisting disease (P 0.015). However,
not available, 24 men were not eligible, and four men subjects that were interviewed were more likely to have
had language barriers, leaving a total of 390 subjects who lower mean IIEF-5 scores (14.1 vs. 10.9, P  0.03) and
were asked to participate. Of these, 88 (22.6%) subjects increased severity of ED (P  0.001).
refused or did not complete the questionnaires. The indi- Subjects’ SF-36 scores were lower in all domains ex-
viduals who refused did not differ from study subjects cept bodily pain and general health perception than
with regard to age. The proportion of subjects younger those reported for an age-matched population without
ESRD [20]. Table 2 summarizes the results of the KDQOLthan 50 years of age was 23% among those who refused
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Table 3. Unadjusted association between KDQOL measures and presence of ED
Patients with ED Patients without ED Mean score Linear regression
QOL measure Mean (SE) Mean (SE) difference (SE) P value
PCS-12a 37.9 (0.8) 43.8 (1.5) 5.9 (1.8) 0.007
MCS-12b 46.7 (1.2) 53.0 (1.5) 6.3 (1.8) 0.005
PCS-36c 36.4 (1.1) 44.2 (1.2) 7.7 (1.7) 0.001
MCS-36d 47.6 (1.5) 54.5 (1.6) 6.9 (2.1) 0.007
There were unadjusted scores available for 266 patients for the SF-12 and 149 patients for the SF-36.
a PCS-12 is the physical composite score of the SF-12
b MCS-12 is the mental composite score of the SF-12
c PCS-36 is the physical composite score of the SF-36
d MCS-36 is the mental composite score of the SF-36
Table 4. KDQOL measures that may be associated with EDin the study population overall, in subjects with ED, and
in subjects without ED. The overall health-rating question Mean score Linear regression
Domain difference (SE)a P valuefrom the KDQOL was 61.7 (21.3) among all subjects.
ESRD-targeted areasb
Symptom/problem 8.3 (2.7) 0.009Evaluation of the relationship between
Burden of kidney disease 11 (5.5) 0.07ED and depression
Work status 4.0 (8.9) 0.66
Cognitive function 9.0 (3.8) 0.03Using the question “Have you felt so down in the dumps
Quality of social interaction 10.3 (1.9) 0.001that nothing could cheer you up?” to classify depression,
Sleep 12 (3.7) 0.007
9.7% of the subjects were classified as depressed. Using Social support 8.7 (6.3) 0.19
Dialysis staff encouragement 3.1 (5.1) 0.56the question “Have you felt downhearted and blue?”
Patient satisfaction 15.1 (3.5) 0.00114.6% of subjects were classified as depressed. There
36-item health survey scales
was no statistically significant association between ED Physical functioning 16.9 (4.9) 0.004
Role–physical 20.1 (9.5) 0.06and depression using either question. Depression in-
Pain 15.2 (4.2) 0.004creased to 26.2% if we used a positive response to either
General health perceptions 11.5 (3.2) 0.004
question as presence of depression. Although depression Emotional well-being 12.9 (3.7) 0.005
Role–emotional 22.9 (7.6) 0.01was found in 19.4% of individuals without ED and in
Social function 17.8 (4.1) 0.00127.2% of individuals with ED, we were unable to find
Vitality 11.3 (3.3) 0.005
an association between depression and ED (OR  1.46,
a Adjusted for diabetes, age, albumin, time on dialysis, and index of coexisting95% CI, 0.64 to 3.35, P  0.3). disease score.
b Effects of kidney disease domain not included since it contains questions
about sexual history.Evaluation of the relationship between ED and
quality of life
Among the 149 patients who completed all the
KDQOL items, ED was statistically and significantly cline in MCS-12 was also statistically significant using the
associated with all individual SF-36 scales. Men with ED IIEF severity scale (P  0.005) and the MMAS question
had significantly lower scores than did men without ED (P  0.001).
on the physical (36.4 vs. 44.2, respectively; P  0.001) The presence of ED was a statistically significant pre-
and mental (47.6 vs. 54.5, respectively; P 0.007) scales. dictor of lower physical and mental composite scores
Among the 266 patients for whom we had complete data even after adjusting for age, diabetes, and ICED score. In
on the SF-12, the mean (SD) SF-12 mental score was 48 regression models for different quality-of-life measures,
(11.0). The mean (SD) SF-12 physical score was 39 (9.3). ED was associated with poorer social interaction, less
In unadjusted analyses, lower physical and mental scores emotional well-being, and more role limitations due to
were significantly associated with ED (Table 3). Using emotional problems, all adjusted for age group, presence
the physical and mental components of the SF-12 as of diabetes, albumin, time on dialysis, and ICED score
predictors of ED, only the mental composite score (MCS) (Table 4).
was statistically significant (P  0.008) after adjusting
for age and diabetes.
DISCUSSIONWe examined the dose-response relationship between
ED and quality-of-life. Using the IIEF severity scale and ED is a common, but likely underdiagnosed, health
issue. We explored different quality of life measuresthe supplemental single-item scale question separately,
the physical component scores of the SF-12 showed a in HD patients that we hypothesized a priori may be
associated with ED: We found the emotional domainsstatistically significant decline as the severity of ED in-
creased (P  0.006 and P  0.003, respectively). The de- of the SF-36 to be profoundly associated with ED. This
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association of ED with diminished quality of life was Furthermore, all our measures of ED were self-reported
and no other physical or diagnostic tests were performed,independent of age, presence of diabetes, and other co-
morbidities, as assessed by the ICED score. which resembles today’s clinical practice. We attempted
to standardize self-report of ED by using a questionnaireOur subjects’ SF-36 scores were lower than an age-
matched general population in all domains except bodily that had been validated in other settings [12, 13]. Finally,
because the presence of ED and associated conditionspain and general health perception [17], but are similar
to results found in other dialysis studies [21, 22]. For and exposures were assessed simultaneously, it was im-
possible to determine if we identified causal associations.example, the mean physical functioning domain score in
the HD group was 54.2 (27.8) versus 79.9 (25.5) for men There have been new therapies developed for the treat-
ment of ED, including oral sildenafil, which has yieldedbetween the ages of 55 to 64 in the general U.S. popula-
tion [17]. Treatment of ED in patients without renal encouraging results in some studies [33–35], while others
have shown poor results [36].insufficiency has been associated with improvements in
mental health scores [23, 24], social health scores [23], Recent advances in therapies of ED warrant the diag-
nosis and treatment of ED be included in the globaland self-esteem scores [23] using the Duke health profile,
a quality-of-life questionnaire. health assessment by the nephrologist and primary care
provider of patients with renal insufficiency, as it mayOther non-ESRD subjects have also demonstrated the
relationship between ED and the emotional domains of improve the quality of life of our patients. However,
further studies are needed that will assess changes inthe SF-36. ED may lead to depressive symptoms, low
self-esteem, and decreased overall quality of life [10, 25, quality of life after ED therapy in patients with ESRD.
26]. Although there is no accepted standard definition
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